Merck suspends trial enrollment

SurModics says that Merck informed the company that results reported in a recently published study comparing laser treatment and intravitreal injections of triamcinolone acetonide in patients with diabetic macular edema prompted Merck to reevaluate the design of its Phase IIb clinical trial for I-vation TA. Pending the review, Merck is suspending enrollment of new patients in the Phase IIb clinical trial. The License and Research Collaboration Agreement with Merck continues, and other ongoing development programs with Merck are unaffected. Release

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.